The AMA, along with 36 other medical societies, is petitioning CMS and the Office of the National Coordinator for Health Information Technology for changes to how it measures interoperability of electronic health records.According to an AMA press relea…
Author: Healio ophthalmology
Early data ‘promising’ for gene therapy for Leber’s hereditary optic neuropathy
GenSight Biologics reported “promising” preliminary data on its gene therapy product for the treatment of neurodegenerative retinal disease, according to a press release.The study included 15 patients with Leber’s hereditary optic neuropathy (LHON) grouped into five groups, with each group of three patients receiving an escalating dose of GS010 via single intravitreal injection in the more severely affected eye. Mean onset of disease was 6 years. Enrollment in the phase 1/2 safety and tolerability study was completed in April 2015.
Glaukos reports 57% increase in net sales in first quarter
Glaukos reported net sales of $23.1 million in the first quarter, a 57% increase from $14.7 million in the same quarter of 2015, according to a press release. The growth was attributed to increased use of the iStent among a growing customer base.
VIDEO: Surgeon shares pearls for intraoperative aberrometry
At Hawaiian Eye, John A. Hovanesian, MD, FACS, shares pearls for the use of intraoperative aberrometry as a valuale tool for improving patient outcomes.
VIDEO: Advantages of small aperture IOLs
At Hawaiian Eye, John A. Vukich, MD, talks about the advantages of small aperture extended depth of focus IOLs.
VIDEO: Next generation presbyopia implants
At Hawaiian Eye, Roger F. Steinert, MD, discusses why he believes IOLs are a powerful instrument in correcting refractive errors.
Aerie reports net loss of $22.7 million in first quarter
Aerie Pharmaceuticals reported a GAAP net loss of $22.7 million, or $0.85 per share, in the first quarter compared with a GAAP net loss of $17.2 million, or $0.70 per share, in the same quarter of 2015, according to a press release.Operating expenses w…
Pixium receives approval to initiate clinical trial of bionic vision system
The Medicines and Healthcare Products Regulatory Agency in the United Kingdom has granted approval for Pixium Vision to initiate a clinical trial of the Iris II bionic vision system in patients who have lost sight due to retinitis pigmentosa, according…
ThromboGenics receives FDA approval for new formulation of Jetrea
The Office of Biotechnology Products of the FDA has approved an already diluted formulation of Jetrea, according to a press release from ThromboGenics. The new Jetrea (ocriplasmin) formulation eliminates “the current preparatory dilution steps prior to injection.” According to the release, when Jetrea is administered to the eye, the strength, potency, composition and pharmaceutical form of the new formulation will remain identical to the currently available formulation of Jetrea after dilution.
VIDEO: Surgeon discusses future of IOL calculations with Ladas Super Formula, Super Surface
At Hawaiian Eye, Uday Devgan, MD, talks about the advantages of the Ladas’ Super Formula, Super Surface for IOL calculations.
VIDEO: Role of OCT angiography in central serous chorioretinopathy
At Retina 2016, Jay S. Duker, MD, discusses the use of OCT angiography in patients with central serous chorioretinopathy.
Repeated anti-VEGF injections for neovascular AMD increase IOP
Anti-VEGF injections increased IOP in eyes being treated for neovascular age-related macular degeneration, according to a study.“Overall, our data support an ocular hypertensive action of anti-VEGF drugs probably mediated by a direct action on the trabecular meshwork,” the study authors said.
AGTC receives orphan medicinal product designation for retinitis pigmentosa gene therapy in Europe
The European Commission has granted orphan medicinal product designation to an investigational gene therapy for the treatment of X-linked retinitis pigmentosa caused by mutations in the RPGR gene, according to a press release from Applied Genetic Technologies Corporation. “Receiving orphan medicinal product designation from the [European Commission] for our XLRP gene therapy candidate is an important milestone for AGTC and a positive step forward in our ongoing efforts to develop effective treatments for rare inherited retinal diseases,” Sue Washer, president and CEO of AGTC, said in the release.
Técnica de ATC orientada por sutura é útil em casos de cirurgias complexas
Os avanços nos dispositivos prostéticos intraoculares na cirurgia de catarata, tais como os anéis de tensão capsular, dispositivos de tensão capsular e ganchos de suporte da cápsula, têm ajudado a elevar o nível de excelência cirúrgica da cirurgia de catarata. Os cirurgiões podem executar cirurgias seguras na presença de fraqueza zonular, lise zonular ou instabilidade capsular e colocar com segurança uma LIO da câmara posterior dentro da bolsa capsular estabilizada por anel de tensão capsular, normalmente com um resultado cirúrgico favorável. No passado, tais casos poderiam terminar com uma extração (Read more...)
Técnica CTR guiada por sutura útil en casos de cirugías complejas
Los avances en los dispositivos de prótesis intraocular en la cirugía de cataratas, como los anillos de tensión capsular, los dispositivos de tensión capsular y ganchos de soporte capsular, ayudaron a que la cirugía de cataratas escale a un nivel mayor de excelencia quirúrgica. Los cirujanos pueden realizar cirugías seguras en presencia de debilidad zonular, lisis zonular o inestabilidad capsular y colocar un LIO de cámara posterior de manera segura dentro del saco capsular estabilizado por el anillo de tensión capsular, en general, con un resultado quirúrgico favorable. En el (Read more...)
Procedimiento de CLASS: Tratamiento del glaucoma menos invasivo
El glaucoma, la segunda causa principal de ceguera en todo el mundo, generalmente se trata con medicamentos tópicos hipotensivos. Si bien son efectivos para reducir la PIO cuando se utilizan de manera correcta, el cumplimiento por parte del paciente continúa siendo un asunto preocupante. Con frecuencia, el aumento de los costos, la inconveniencia extrema, la administración difícil y la tolerancia adaptada a los medicamentos limitan los beneficios de estos medicamentos de sobremanera.Se consideran las intervenciones quirúrgicas una vez que un paciente alcanzó un nivel base de PIO de aproximadamente 18 (Read more...)
Procedimento CLASS: Tratamento de glaucoma menos invasivo
O glaucoma, a segunda maior causa de cegueira no mundo todo, tradicionalmente é tratado com medicações tópicas hipotensivas. Embora elas sejam eficazes na redução da PIO quando utilizadas corretamente, a conformidade do paciente continua sendo um problema preocupante. A elevação dos custos, a extrema inconveniência, a dificuldade de administração e a tolerância adaptada aos medicamentos com frequência limitam gravemente os benefícios dos mesmos.Uma vez que um paciente tenha atingido uma linha de base de PIO de cerca de 18 mm Hg e esteja na dosagem máxima da medicação, são consideradas (Read more...)
VIDEO: Study shows Omidria reduces need for pupillary expansion devices in cataract surgery
NEW ORLEANS — At the American Society of Cataract and Refractive Surgery meeting, Denise Visco, MD, discusses a retrospective study showing that use of Omidria, a 1% phenylephrine and 0.3% ketorolac agent from Omeros, in the balanced salt solution bottle during cataract surgery reduced the need for pupillary expansion devices in small pupil cases compared with use of epinephrine.
EyeGate reports $2.4 million net loss in first quarter
EyeGate Pharmaceuticals reported a net loss of $2.4 million in the first quarter compared with a net loss of $11 million in the same quarter of 2015, according to a press release. Research and development expenses were reported at $0.9 million in the first quarter compared with $0.3 million in the same quarter of 2015. The increase was attributed to the resumption of a phase 3 clinical trial for the treatment of anterior uveitis, a phase 1/2 macular edema trial, and research and development expenses related to Jade’s CMHA-S-based product (Read more...)
BLOG: Intralenticular foreign body
Intraocular foreign bodies, or FB, are usually the result of penetrating traumatic wounds that may land the FB into either the anterior or posterior chamber, depending upon the type of injury. Isolated intralenticular foreign bodies are rarely seen, and they soon lead to cataract formation. Some cases have been reported in peer literature about asymptomatic foreign bodies lying in the normal crystalline lens.